Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA141062)
Article History
Received: 8 July 2020
Revised: 6 February 2021
Accepted: 16 February 2021
First Online: 23 March 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: Y.K. holds equity interest in KayoThera and Firebrand Therapeutics.
: The work in the authors’ laboratory is supported by grants from the Brewster Foundation, American Cancer Society, Susan G. Komen Foundation, Breast Cancer Research Foundation, the NIH and the U.S. Department of Defense to Y.K.